The heart of any arranger keyboard is its style engine and auto-accompaniment system, which transforms simple chord inputs into fully realized musical arrangements. Play a C major chord, and the ...

UK-based Ignota Labs has acquired all of the clinical-stage assets in Kronos Bio's pipeline, after the US company ceased operations earlier this year. Ignota specialises in turning around promising ...

The new Kronos IEMs from have nine drivers and a six-way crossover but an impedance of less than 35Ω. Noble Audio has announced the launch of its latest pair of flagship in-ear monitors. The Kronos ...

Noble Kronos flagship IEMs deliver cutting-edge 9-driver hybrid sound with titanium shells. Are these $4,500 earphones worth the hype and price? Now, before you roll your eyes at the $4,500 price tag ...

CAMBRIDGE, Mass., May 01, 2025 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. ("Kronos Bio") (Nasdaq: KRON), a biotechnology company that has been developing small molecule therapeutics to address cancers and ...

Kronos Bio is vacating its corporate headquarters amid a wider cost-cutting exercise for the struggling biotech. The company, which has been focused on developing small-molecule drugs for cancers and ...

Performances in N.Y.C. Advertisement Supported by The venerable quartet returned to Zankel Hall with a typically eclectic program and a newfound emotional intensity. By Corinna da Fonseca-Wollheim The ...

Big names returned to the annual National Association of Music Merchants Show in 2025, bringing with them a plethora of musical products from the old school to the futuristic. Companies like Boss, ...

Add Yahoo as a preferred source to see more of our stories on Google. When you buy through links on our articles, Future and its syndication partners may earn a commission. Credit: Korg NAMM 2025: ...

New more versatile sound engine. Vocoder, hardtune and harmonizer vocal effects. Solid build. Excellent color screen. The MicroKorg 2 is an improvement on the original in almost every way, that much ...

On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would roll out “significant expense reduction strategies” to buy itself more time.